Is Palatin Technologies, Inc. (PTN) a Buy, Sell, or Hold?
NASDAQ : PTN
Palatin Technologies, Inc.
$8.48 USD
-$0.61 (-6.71%)
- Volume
- 11.28K
- Average Volume
- 16.91K
- Market Capitalization
- $15.09M
- P/E Ratio
- -1.82
- Dividend Yield
- 0.00%
- Price Target
- $47.50
- Year High
- $31.00
- Year Low
- $5.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.04
Company Overview
NASDAQ
Carl Spana
Biotechnology
Healthcare
PTN
29
US
USD
Liquidity Metrics
0.03
5.04
5.04
4.01
0.00
Sales & Valuation
-$
1.17
0.78
-1.01
-15.42
Profitability
-$32.15
-$17.31M
-48.50%
-48.50%
-141.40%
-47.25%
P/E Metrics
-1.82
0.00
0.00
Analyst Price Target & Rating
$47.50
$47.50
$47.50
3/5
3 Analysts
-82.15%
Financial Health Scores
5.18
4/9
$10.25M
$13.23M
$2.63M
-$6.24M
Key Metrics (TTM)
$5.23M
0.41
-0.85
5.04
-141.40%
-59.93%
-75.75%
-99.19%
-19661 days
Company Executives
| Name | Title |
|---|---|
| John Dodd | Senior Vice President of Preclinical Development |
| Robert Jordan | Senior Vice President of Program Operations |
| Stephen A. Slusher | Chief Legal Officer |
| James E. Hattersley | Senior Vice President of Business Development |
| Burns McClellan | Vice President of Investor Relations |
| Carl Spana | Co-Founder, President, Chief Executive Officer & Director |
| Stephen T. Wills | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Palatin Technologies, Inc. (NASDAQ:PTN) Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey. ...
Palatin to Begin Trading on Nasdaq Stock Exchange
2026-05-18 16:00:00
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
2026-05-13 15:00:50
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-05-13 07:30:00
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026 Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027 Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use Conference call and webcast scheduled for May 13, 2026, at 11:00 a.m. ET PRINCETON, N.J.
Frequently Asked Questions
-
What is the current Palatin Technologies, Inc. (PTN) stock price?
-
Palatin Technologies, Inc.(NASDAQ:PTN) stock price is $8.48 in the last trading session. During the trading session, PTN stock reached the peak price of $31 while $5 was the lowest point it dropped to. The percentage change in PTN stock occurred in the recent session was --6.71% while the dollar amount for the price change in PTN stock was -$0.61.
-
PTN's industry and sector of operation?
-
The NASDAQ listed PTN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PTN?
-
John Dodd | Senior Vice President of Preclinical Development
Robert Jordan | Senior Vice President of Program Operations
Stephen A. Slusher | Chief Legal Officer
James E. Hattersley | Senior Vice President of Business Development
Burns McClellan | Vice President of Investor Relations -
How many employees does PTN have?
-
Number of PTN employees currently stands at 29. PTN operates from 11 Deer Park Drive, Monmouth Junction, NJ 08512, US.
-
Link for PTN official website?
-
Official Website of PTN is: https://palatin.com
-
How do I contact PTN?
-
PTN could be contacted at phone #609 495 2200 and can also be accessed through its website. PTN operates from 11 Deer Park Drive, Monmouth Junction, NJ 08512, US.
-
How many shares of PTN are traded daily?
-
The average number of PTN shares traded daily for last 3 months was 16.91K.
-
What is the market cap of PTN currently?
-
The market value of PTN currently stands at $15.09M with its latest stock price at $8.48